SUNY-Buffalo: Newly Diagnosed Children, Young Adults With Type 1 Diabetes Preserve Endogenous Insulin Production With Anti-TNF Drug
June 16, 2020
June 16, 2020
BUFFALO, New York, June 16 -- The State University of New York Buffalo campus issued the following news release:
In research led by a University at Buffalo pediatric endocrinologist, a drug called golimumab showed that it preserved beta-cell function in children and young adults with newly diagnosed Type 1 diabetes, according to findings from a Phase 2 study.
The study also demonstrated that golimumab, an anti-tumor-necrosis-factor (TNF) therapy, reduced the amount of i . . .
In research led by a University at Buffalo pediatric endocrinologist, a drug called golimumab showed that it preserved beta-cell function in children and young adults with newly diagnosed Type 1 diabetes, according to findings from a Phase 2 study.
The study also demonstrated that golimumab, an anti-tumor-necrosis-factor (TNF) therapy, reduced the amount of i . . .